Lung cancer trials in Argentina

In Argentina 47 Also abroad 2733

47 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2/3Taking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Belgrano, Buenos Aires, Ciudad Autonoma de Buenos Aires, Ciudad Autónoma de Buenos Aires, Córdoba, Pergamino, Porto Alegre, Río Cuarto, Rosario, San Pedro, Viedma
Age
18 years and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
Phase 3Taking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Buenos Aires, Ciudad Autonoma Buenos Aires, Ciudad Autonoma de Buenos Aire, Viedma
Age
18 years and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
Phase 3Taking people
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Where
Bariloche, Buenos Aires, Ciudad Autónoma de Buenos Aires, Mar del Plata, Río Cuarto, Rosario
Age
18 years and over
People
851 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Where
Buenos Aires, CABA, La Plata, Pilar, Rosario
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Where
Buenos Aires, CABA, La Plata, Pilar, Rosario
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00
Phase 1/2Taking people
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Where
Buenos Aires, Ciudad Autonoma de Buenos Aire
Age
18 years and over
People
252 worldwide
Run by
AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00
Phase 3Taking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
ABB, CABA, Ciudad Autónoma de Buenos Aires, Ciudad de Buenos Aires, Pilar, Rosario
Age
18 years and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Where
Buenos Aires, Ciudad Autonoma Buenos Aires, Córdoba, Pergamino, Pilar, Rosario, San Juan
Age
18 years and over
People
686 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00
Phase 2/3Taking people
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Where
Buenos Aires, CABA, Ciudad Autónoma de Buenos Aires, Lujan de Cuyo, Río Cuarto, Rosario
Age
18 years and over
People
590 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00
Phase 3Taking people
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Buenos Aires, Córdoba, Mar del Plata, Rosario, San Miguel de Tucumán
Age
18 years and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
Phase 2Taking people
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Buenos Aires, Rosario, Viedma
Age
18 years and over
People
160 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680764 · EU 2026-525170-19-00
Phase 3Taking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Buenos Aires, San Juan, San Miguel de Tucumán, Santa Fe
Age
18 years and over
People
695 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06801834
Phase 3Taking people
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Where
Ciudad Autónoma de Buenos Aires, Córdoba, Pergamino, Pilar
Age
18 years and over
People
360 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00
Phase 2/3Taking people
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Where
ABB, Ciudad Autónoma de Buenos Aires, Córdoba
Age
18 years and over
People
500 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07100080
Phase 3Taking people
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Buenos Aires, CABA, Ciudad Autónoma de Buenos Aires, Córdoba, Florida, La Rioja, Mar del Plata, Mendoza, Pergamino, Pilar
Age
18 years and over
People
1,410 worldwide
Run by
Pfizer
See details and how to joinNCT07222566 · EU 2025-523461-17-01
Phase 1/2Taking people
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Where
Pilar, Rosario
Age
18 years and over
People
327 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06780137 · EU 2024-517926-25-00
Phase 2Taking people
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Where
Caba., Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires., Mar del Plata, Rosario
Age
18 years and over
People
180 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07221474 · EU 2025-520902-37-00
Phase 3Taking people
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Where
Córdoba, Rosario
Age
18 years and over
People
450 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00
Phase 3Taking people
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Where
Berazategui, Buenos Aires, Cipolletti, Ciudad Autonoma de Buenos Aires, Córdoba, Florida, Mar del Plata, Pergamino, Rosario, San Juan, San Salvador de Jujuy
Age
18 years and over
People
714 worldwide
Run by
Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Where
CABA, Córdoba, Pilar, Rosario, Viedma
Age
18 years and over
People
830 worldwide
Run by
AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00
No phaseTaking people
Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
Where
Buenos Aires
Age
18 years and over
People
200 worldwide
Run by
Latin American Cooperative Oncology Group
See details and how to joinNCT07192991
No phaseTaking people
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
Where
Rosario
Age
40 years to 75 years
People
6,000 worldwide
Run by
Javier Toledo
See details and how to joinNCT06717295